Scannell Timothy J 4

What Happened

• Timothy J. Scannell, a director of NovoCure Ltd. (NVCR), was granted equity awards on 2026-06-03. He received 11,610 restricted stock units (RSUs) and 16,999 derivative awards (no cash paid; exercise/strike price reported as $0.00 in the filing). These are awards/grants rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (filed within the normal two-business-day window).
• Award amounts and reported price: 11,610 shares @ $0.00 (RSUs); 16,999 shares @ $0.00 (derivative award).
• Shares owned after transaction: not specified in the provided summary — see the full Form 4 for total beneficial ownership.
• Footnotes:
  • F1: The 11,610 RSUs vest 100% on the earlier of (i) the first anniversary of the grant date or (ii) the day before NovoCure’s 2027 annual general meeting.
  • F2: The 16,999 derivative awards are options that will fully vest and become exercisable on the earlier of (i) the first anniversary of the grant date or (ii) the day before the 2027 annual general meeting.
• No indication of a 10b5-1 plan, tax withholding sale, or gift in the provided data.

Context

• These are company-granted awards (compensation), which are routine for executives and directors; they do not reflect an open-market purchase or sale. The derivative portion appears to be options that will vest per the schedule in F2 — not an immediate exercise or cashless sale. For complete ownership impact and vesting details, consult the full Form 4 filing.